Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A 2020 THESIS Questionnaire Survey of Members of the Swedish Endocrine Society
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: The standard treatment of hypothyroidism is levothyroxine (LT-4). However, there are several controversies regarding treatment of hypothyroid patients. Aim: To investigate the Swedish endocrinologists’ use of thyroid hormones in hypothyroid and euthyroid individuals. Methods: Physician members of the Swedish Endocrine Society (SEF) were invited by e-mail to participate in an online survey investigating this topic. Results: Out of the eligible 411 members, 116 (28.2%) responded. The majority (98.9%) stated that L-T4 is the treatment of choice. However, around 50% also prescribed liothyronine (L-T3) or a combination of L-T4+L-T3 in their practice. Combination therapy was mostly (78.5%) used in patients with persistent hypothyroid symptoms despite biochemical euthyroidism on L-T4 treatment. Most respondents prescribed L-T4 tablets and did not expect any major changes with alternative formulations such as soft-gel capsules or liquid formulations in situations influencing the bioavailability of L-T4. In euthyroid patients, 49.5% replied that treatment with thyroid hormones was never indicated, while 47.3% would consider L-T4 for euthyroid infertile women with high thyroid peroxidase (TPO) antibody levels. Conclusion: The treatment of choice for hypothyroidism in Sweden is L-T4 tablets. Combination therapy with L-T4+L-T3 tablets was considered for patients with persistent symptoms despite biochemical euthyroidism. Soft-gel capsules and liquid solutions of L-T4 were infrequently prescribed. Swedish endocrinologists’ deviation from endocrine society guidelines merits further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
Global epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552
Thangaratinam, S., Tan, A., Knox, E., Kilby, M. D., Franklyn, J., & Coomarasamy, A. (2011) · BMJ · doi:10.1136/bmj.d2616 · Cited by 604
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437 · cited 15×
“%) would suggest it in hypothyroid patients with normal TSH complaining of unexplained weight gain (combination therapy vs. never use; p<0.001).”
BackgroundInfluentialLevothyroxine in Women with Thyroid Peroxidase Antibodies before Conception
Dhillon-Smith, R. K., Middleton, L. J., Sunner, K. K., Cheed, V., Baker, K., Farrell-Carver, S., Bender-Atik, R., Agrawal, R., Bhatia, K., Edi-Osagie, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812537 · Cited by 303 · cited 1×
“The rationale is to secure euthyroidism in case of pregnancy, although current evidence from randomized trials (38, 39) suggests that L-T4 treatment neither increases fertility rates nor reduces the risk of adverse pregnancy outcomes in these individuals.”
ResultTaylor, P. N., Iqbal, A., Minassian, C., Sayers, A., Draman, M. S., Greenwood, R., Hamilton, W., Okosieme, O., Panicker, V., Thomas, S. L., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11312 · Cited by 300
Grozinsky-Glasberg, S., Fraser, A., Nahshoni, E., Weizman, A., & Leibovici, L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0448 · Cited by 296
Selenium in thyroid disorders—essential knowledge for clinicians
Winther, K. H., Rayman, M. P., Bonnema, S. J., & Hegedüs, L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0311-6 · Cited by 288 · cited 1×
“This result is probably based on insufficient evidence for clinical efficacy of selenium supplementation (48), despite evidence of an effect on TPOAb concentrations (49), and the fact that the Swedish population is considered iodine sufficient from iodine fortification of salt since 1936 (50, 51).”
BackgroundSelf-citationAn Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hennessey, J. V., Kopp, P. A., Ross, D. S., Samuels, M. H., Sawka, A. M., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0681 · Cited by 231 · cited 1×
“Approximately 10% of patients treated with L-T4 for hypothyroidism report persisting hypothyroid symptoms despite biochemical euthyroidism (11).”
BackgroundTreatment of Hypothyroidism with Combinations of Levothyroxine plus Liothyronine
Escobar-Morreale, H. F., Botella-Carretero, J. I., del Rey, F. E., & de Escobar, G. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0184 · Cited by 160
Hoang, T. D., Olsen, C. H., Mai, V. Q., Clyde, P. W., & Shakir, M. K. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4107 · Cited by 151
Levothyroxine overuse: time for an about face?
Rodriguez-Gutierrez, R., Maraka, S., Ospina, N. S., Montori, V. M., & Brito, J. P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30276-5 · Cited by 100 · cited 1×
“As in other countries (5, 6), the number of L-T4 prescriptions has recently increased in Sweden (7).”
BackgroundAbrahamsen, B., Jørgensen, H. L., Laulund, A. S., Nybo, M., Bauer, D. C., Brix, T. H., & Hegedüs, L. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2416 · Cited by 98
Self-citationThyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism
Chao, M., Jiawei, X., Xia, H., Guoming, W., Yangang, W., Xufu, W., & Shuyao, Z. (2009) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32832c79e0 · Cited by 93
Thvilum, M., Brandt, F., Almind, D., Christensen, K., Brix, T. H., & Hegedüs, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075789 · Cited by 92 · cited 1×
“According to the European guidelines, L-T4 + L-T3 combination therapy might be considered as a trial in L-T4-treated patients who have persistent complaints despite biochemical euthyroidism after exclusion of other autoimmune diseases and comorbidities (2), the latter being very prevalent in patients with hypothyroidi…”
BackgroundSelf-citationShakir, M. K. M., Brooks, D. I., McAninch, E. A., Fonseca, T. L., Mai, V. Q., Bianco, A. C., & Hoang, T. D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab478 · Cited by 92 · cited 1×
“org 2 L-T4 and L-T3, among other substances, is, in Sweden, only available with an individual license approved by the Swedish Medical Products Agency due to limited scientific evidence for its benefit (22, 23).”
BackgroundMitchell, A. L., Hegedüs, L., Žarković, M., Hickey, J. L., & Perros, P. (2021) · Clinical Endocrinology · doi:10.1111/cen.14340 · Cited by 81
Self-citationLiothyronine use in a 17 year observational population‐based study ‐ the tears study
Leese, G. P., Soto‐Pedre, E., & Donnelly, L. A. (2016) · Clinical Endocrinology · doi:10.1111/cen.13052 · Cited by 75 · cited 1×
“Data on long-term safety are limited (20, 21).”
BackgroundPerros, P., Van Der Feltz‐Cornelis, C., Papini, E., Nagy, E. V., Weetman, A. P., & Hegedüs, L. (2023) · Clinical Endocrinology · doi:10.1111/cen.14473 · Cited by 65
Self-citationMedici, B. B., Nygaard, B., la Cour, J. L., Grand, M. K., Siersma, V., Nicolaisdottir, D. R., Lind, B., Olivarius, N. D. F., & Andersen, C. L. (2019) · Thyroid® · doi:10.1089/thy.2018.0539 · Cited by 63
Michaelsson, L. F., Medici, B. B., la Cour, J. L., Selmer, C., Røder, M., Perrild, H., Knudsen, N., Faber, J., & Nygaard, B. (2015) · European Thyroid Journal · doi:10.1159/000437262 · Cited by 57 · cited 1×
“Many unsubstantiated claims of the positive effects of L-T3 treatment are aired online and via patient organizations, resulting in an increasing number of patients requesting treatment with L-T3 (13, 14).”
BackgroundJoffe, R. T., Brimacombe, M., Levitt, A. J., & Stagnaro-Green, A. (2007) · Psychosomatics · doi:10.1176/appi.psy.48.5.379 · Cited by 57
Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients; the 2019 Italian Survey
Negro, R., Attanasio, R., Nagy, E. V., Papini, E., Perros, P., & Hegedüs, L. (2020) · European Thyroid Journal · doi:10.1159/000502057 · Cited by 52 · cited 9×
“To date, the Italian (24), Bulgarian (25), Romanian (26), Polish (27), Spanish (28), and Danish (29) national surveys have been published.”
BackgroundResultInfluentialSelf-citationPhysician Choice of Hypothyroidism Therapy: Influence of Patient Characteristics
Jonklaas, J., Tefera, E., & Shara, N. (2018) · Thyroid · doi:10.1089/thy.2018.0325 · Cited by 41
Akirov, A., Fazelzad, R., Ezzat, S., Thabane, L., & Sawka, A. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00477 · Cited by 37 · cited 1×
“To date, a number of randomized controlled trials have studied the effect of combined L-T4+L-T3 and five systemic reviews/meta-analyses have concluded that the combined treatment is not superior to standard L-T4 treatment with respect to hypothyroid symptoms and quality of life (15–18) or patient preference (19).”
BackgroundRiis, K. R., Frølich, J. S., Hegedüs, L., Negro, R., Attanasio, R., Nagy, E. V., Papini, E., Perros, P., & Bonnema, S. J. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01555-y · Cited by 37
Self-citationLiothyronine Use in Hypothyroidism and its Effects on Cancer and Mortality
Planck, T., Hedberg, F., Calissendorff, J., & Nilsson, A. (2021) · Thyroid® · doi:10.1089/thy.2020.0388 · Cited by 35
Self-citationBednarczuk, T., Attanasio, R., Hegedüs, L., Nagy, E. V., Negro, R., Papini, E., Perros, P., & Ruchała, M. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0048 · Cited by 33
Self-citationNiculescu, D. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.462 · Cited by 28
Liothyronine cost and prescriptions in England
Taylor, P. N., Razvi, S., Muller, I., Wass, J., Dayan, C. M., Chatterjee, K., & Boelaert, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30334-6 · Cited by 19
Cited by
Perros, P., Nagy, E. V., Papini, E., Van Der Feltz-Cornelis, C. M., Weetman, A. P., Hay, H. A., Abad-Madroñero, J., Tallett, A. J., Bilas, M., Lakwijk, P., et al. (2023) · Thyroid · doi:10.1089/thy.2022.0641 · Cited by 27
Younes, Y. R., Perros, P., Hegedüs, L., Papini, E., Nagy, E. V., Attanasio, R., Negro, R., & Field, B. C. T. (2023) · Clinical Endocrinology · doi:10.1111/cen.14812 · Cited by 19
Self-citationAttanasio, R., Žarković, M., Papini, E., Nagy, E. V., Negro, R., Perros, P., Akarsu, E., Alevizaki, M., Ayvaz, G., Bednarczuk, T., et al. (2024) · Thyroid® · doi:10.1089/thy.2023.0580 · Cited by 18
Self-citationRiis, K. R., Larsen, C. B., & Bonnema, S. J. (2024) · Thyroid® · doi:10.1089/thy.2023.0649 · Cited by 10
Metadata
- Authors
- Planck, T., Lantz, M., Perros, P., Papini, E., Attanasio, R., Nagy, E. V., & Hegedüs, L.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2021-12-06
- Volume
- 12
- Pages
- 795111-795111
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W4200498494
- Cited by
- 23
- References
- 32
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.